earnings
confidence high
sentiment positive
materiality 0.75
Moderna Q3 net income $13M, revenue $1.9B; reiterates FY product sales $3-3.5B
Moderna, Inc.
2024-Q3 EPS reported
-$6.37
revenue$2,270,000,000
- GAAP net income $13M ($0.03 EPS) vs net loss of $3.6B in Q3 2023; revenue $1.9B.
- Net product sales $1.8B (+4% YoY); COVID-19 sales $1.8B, RSV sales $10M (below expectations).
- FY 2024 product sales guidance reiterated at $3.0-3.5B; cost of sales guidance narrowed to 40-45%.
- R&D lowered to $4.6-4.7B; capex raised to ~$1.2B including Norwood campus purchase ($0.4B).
- Initiated Phase 3 trials for norovirus and influenza vaccines; expanded Executive Committee.